Consolidated lawsuits have been filed alleging that GLP-1 drugs, such as Ozempic, Wegovy, Mounjaro, and Zepbound, can cause serious health problems, including non-arteritic anterior ischemic optic neuropathy (NAION), pancreatitis, gallstones, and other digestive or neurological injuries [1][2]. One notable case involves Todd Engel, who claims that using Ozempic resulted in NAION and subsequent blindness, asserting that Novo Nordisk did not adequately warn patients and doctors about this risk [1].
A study published in JAMA Ophthalmology in mid-2026 indicated higher rates of NAION among diabetic patients taking semaglutide, the active ingredient in Ozempic. However, medical groups such as the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society emphasize that the study shows correlation, not causation, and do not recommend patients discontinue GLP-1 medications [1].
The FDA’s adverse-events database has recorded over 1,000 reports of optic neuropathy linked to GLP-1s since 2024, out of nearly 190,000 total reports. Additionally, there are approximately 1,928 reports of pancreatitis, including 135 cases of necrotizing pancreatitis [1][2]. Attorney Jonathan Orent, leading two major multi-district litigations, reports that the cases involve 247 plaintiffs with NAION and over 4,000 plaintiffs with other serious digestive conditions such as pancreatitis or gallstones [1][2].
Novo Nordisk and Eli Lilly, manufacturers of these drugs, have stated they will vigorously defend against these claims, asserting that NAION and other serious conditions are exceedingly rare in clinical trials [1]. The FDA is conducting its own study to assess the risk of NAION associated with GLP-1 drugs and will determine whether regulatory actions, such as changes to warning labels, are necessary [1].
A federal judicial panel has centralized lawsuits alleging blindness from GLP-1 drugs into a multi-district litigation in Pennsylvania [2].
What Is Known
GLP-1 drugs are under scrutiny due to lawsuits alleging they cause serious health issues. The FDA’s adverse-events database contains numerous reports linking these drugs to optic neuropathy and pancreatitis. Legal actions have been centralized in Pennsylvania, and the FDA is investigating the potential risks [1][2].
What Remains Unclear
While lawsuits and studies suggest a correlation between GLP-1 drugs and certain health issues, causation has not been established. The frequency of these adverse effects remains undetermined, and medical groups advise against discontinuing the drugs without further evidence [1].
This article was generated by Bluxle's AI system based on research from multiple news sources. All facts are sourced and cited below. The AI is designed to be neutral and fact-based with no editorial opinion.
Sources & Citations
Weighted by citation frequency — sources cited more often carry greater influence.
Research Basis
This article was researched across outlets representing a range of political perspectives. Only sources whose facts are directly used appear in Sources & Citations above.
Report an Issue
Tell us what you noticed. Our editors will review it.
✓ Report received. Thank you!